ASPG and acute lymphoblastic leukemia: In the largest published prospective study to date, 47 pediatric and adult patients with R/R ALL (40% T cell ALL) received escalating doses of navitoclax (25-100 mg daily) in combination with venetoclax 400 mg daily and chemotherapy/asparaginase.